InfiniumPharmachem Ltd has completed and commissioned its new contrast media raw materials manufacturing facility at GIDC Sojitra, Anand district, Gujarat, effective January 16, 2026. The new unit marks a key milestone in the company’s forward integration strategy, enabling InfiniumPharmachem to enter the contrast media value chain. Building on its established strengths in iodine-based chemistry, the company plans to pursue higher-value opportunities across multiple end-use applications.
The contrast media segment is expected to become a major growth driver for InfiniumPharmachem. Over the next three years, the company is targeting revenue of around ₹100 crore annually from this vertical, with expected EBITDA margins of approximately 30%.
The company also expects the initiative to lift blended EBITDA margins to around 20%. InfiniumPharmachem said the expansion positions it for value-added offerings linked to contrast media applications, supporting pharmaceutical, diagnostic imaging and healthcare markets in line with long-term growth plans.
InfiniumPharmachem Limited (NSE: INFINIUM), headquartered in Anand, Gujarat, manufactures iodine derivatives, pharma intermediates and active pharmaceutical ingredients (APIs). Infinium Pharmachem Limited is an emerging company operating in the pharmaceutical and chemical space, focused on supplying and developing a range of pharmachem products that support healthcare and industrial needs.
The company is associated with the distribution, trading, and possibly manufacturing of pharmaceutical intermediates, active ingredients, and specialty chemicals used in medicine production and related sectors. With increasing demand for high-quality and cost-effective chemical solutions, Infinium Pharmachem Limited aims to play a valuable role in the supply chain by ensuring consistent product availability and maintaining quality standards.
